China Vaccine Market will surpass US$ 12.16 Billion by 2027 at a CAGR of 11.97 Percent according to the publisher. Annually in China, approx. 700 million vaccine doses are produced; China is one of the world's largest producers of vaccines. As a result, China has drawn significant attention to the vaccine industry to play a representative role. In addition, it is a closed market with a solid local vaccine industry, access to which is challenging for Western players.China Vaccine market was US$ 6.91 Billion in 2022
Category 1 & 2 Vaccines in China
In China, Vaccines are available through the government's Expanded Program on Immunization (EPI) at no charge for aged 14 years of children. These government-purchased vaccines are called Category 1 under the Regulations on the Administration of Vaccines and Vaccination. In contrast, private-sector also known as Category 2 vaccines, such as rabies vaccine, influenza vaccine (InfV), and Haemophilus influenza type b vaccine (Hib), are available but are usually paid for out-of-pocket, as they are included in neither the EPI system nor government health insurance. According to our research findings, the China Vaccine market was US$ 6.91 Billion in 2022.Disease Type: Pneumococcal, Meningococcal Meningitis, and DTP Vaccines Controls Significant Portion of China Vaccines Industry
Meningococcal Meningitis, Pneumococcal, and DTP Vaccine market are expected to control a significant portion of China's vaccine market. The vaccine market in China is segmented into Meningococcal meningitis, Pneumococcal, DTP, Ebola, Rabies & Others. In Aug 2021, China formally revised its laws to allow parents to have up to three children to boost the birth rate. In part, thanks to the loosening of the second-child policy in China, the number is expected to increase. China’s vaccine industry has always been more petite and less mature than it’s US, European, or Indian counterparts. However, over the past decades, it has rapidly grown to become one of the only developing countries able to manufacture and supply most vaccines used in its domestic immunization program.Product Insight: PCV13 has Highest Share in the Chinese Vaccine Industry
In terms of products, the Products included in this report are as follows: MCV4, MPSV4, MCV2-Hib, MCV2, MPSV2 and Men A, PCV13, and PPV23. PCV13 holds the maximum share of the China vaccine market. Therefore, it is predicted that PCV13 will also maintain its top place during the forecasting period. In addition, China is the most prominent vaccine consumer in the world. As a result, Chinese residents have become much more aware of preventive health care due to its impact, which has also driven the vaccination rate.Key Company Insights
The major players covered in the report are Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd. In addition, the R&D, clinical, and commercialization experience accumulated by the COVID-19 vaccine would help a group of outstanding domestic Chinese vaccine company’s snowball. Against this backdrop, the Chinese vaccine industry is expected to usher in a golden period. The next decade will be for China's biopharmaceuticals to move from catching up to surpassing a 'golden decade' for the Chinese vaccine industry.May 2022, Walvax Biotechnology Co., Ltd. announced the results for the immunogenicity and safety profile of PCV13, the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, administered as an infant series at 3, 4, and 5 months of age and a booster dose at 12-15 months of age in Chinese infants as part of the randomized, multi-center, double-blind, and positive-controlled phase 3 clinical trial in China to demonstrate the non-inferior immune responses and safety of PCV13 as compared to Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM197 Protein] ('PCV7').
The report titled “China Vaccine Market & Doses Forecast By Sector (Private, Public), Disease Type (Meningococcal Meningitis, Pneumococcal, DTP, Ebola, Rabies, Others), Products (MCV4, MPSV4, MCV2-Hib, MCV2, MPSV2 and Men A, PCV13, PPV23, Others), Company (Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd.)” provides a complete analysis of China Vaccine Market.
Sectors - Vaccine Market & Doses in China
- Public
- Private
Diseases -
1. Meningococcal Meningitis2. Pneumococcal
3. DTP
4. Ebola
5. Rabies
6. Others
Products -
1. MCV42. MPSV4
3. MCV2-Hib
4. MCV2
5. MPSV2 and Men A
6. PCV13
7. PPV23
All the companies covered in the report has been covered from the following points
- Overview
- Recent Development
- Vaccine Pipeline
- Revenue Analysis
Key Company Covered
1. Sinopharm Group (China National Biotec Group Company Limited)2. Hualan Biological Engineering Inc
3. Chongqing Zhifei Biological Products Co Ltd
4. Walvax Biotechnology Co Ltd
5. Beijing Tiantan Biological Products Corp Ltd
6. Sinovac Biotech
7. Shenzhen Kangtai Biological Products Co Ltd
Table of Contents
1. Introduction2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
4.3 Opportunities
5. China Vaccine Market
5.1 Public
5.2 Private
6. China Vaccine Doses
6.1 Public
6.2 Private
7. China Vaccine Share Analysis
7.1 By Sectors Market Share
7.2 By Sectors Vaccine Doses Share
7.3 By Products Type Market Share
7.4 By Disease Type Market Share
8. Meningococcal Meningitis Vaccine Market & Doses Analysis
8.1 Meningococcal Meningitis Vaccine
8.1.1 Public
8.1.2 Private
8.2 Meningococcal Meningitis Doses
8.2.1 Public
8.2.2 Private
9. Pneumococcal Vaccines Market & Doses Analysis
9.1 Pneumococcal Vaccines
9.2 Pneumococcal Vaccines Doses
10. DTP Vaccine Market & Doses Analysis
10.1 DTP Vaccine Market
10.1.1 DTaP
10.1.2 DTcP
10.2 DTP Vaccine Doses
10.2.1 Public
10.2.2 Private
11. Rabies Vaccine Market
12. Ebola Vaccine Market
13. Product - China Vaccine Market
13.1 MCV4
13.2 MPSV4
13.3 MCV2-Hib
13.4 MCV2
13.5 MPSV2 and Men A
13.6 PCV13
13.7 PPV23
13.8 Others
14. The Vaccine Regulatory Authority of China
15. Required and Recommended Vaccinations for China Travel
16. Mergers & Acquisitions
17. Company Sales
17.1 Sinopharm Group (China National Biotec Group Company Limited)
17.1.1 Overview
17.1.2 Recent Initiatives
17.1.3 Net Sales
17.2 Hualan Biological Engineering Inc
17.2.1 Overview
17.2.2 Recent Initiatives
17.2.3 Net Sales
17.3 Chongqing Zhifei Biological Products Co Ltd
17.3.1 Overview
17.3.2 Recent Initiatives
17.3.3 Net Sales
17.4 Walvax Biotechnology Co Ltd
17.4.1 Overview
17.4.2 Recent Initiatives
17.4.3 Net Sales
17.5 Beijing Tiantan Biological Products Corp Ltd
17.5.1 Overview
17.5.2 Recent Initiatives
17.5.3 Net Sales
17.6 Sinovac Biotech
17.6.1 Overview
17.6.2 Recent Initiatives
17.6.3 Net Sales
17.7 Shenzhen Kangtai Biological Products Co Ltd
17.7.1 Overview
17.7.2 Recent Initiatives
17.7.3 Net Sales
List of Figures:
Figure 01: China - Public Vaccine Market (Million US$), 2017 - 2022
Figure 02: China - Forecast for Public Vaccine Market (Million US$), 2023 - 2027
Figure 03: China - Private Vaccine Market (Million US$), 2017 - 2022
Figure 04: China - Forecast for Private Vaccine Market (Million US$), 2023 - 2027
Figure 05: China - Public Vaccine Doses (Million), 2017 - 2022
Figure 06: China - Forecast for Public Vaccine Doses (Million), 2023 - 2027
Figure 07: China - Private Vaccine Doses (Million), 2017 - 2022
Figure 08: China - Forecast for Private Vaccine Doses (Million), 2023 - 2027
Figure 09: Public - Meningococcal Meningitis Vaccine Market (Million US$), 2017 - 2022
Figure 10: Public - Forecast for Meningococcal Meningitis Vaccine Market (Million US$), 2023 - 2027
Figure 11: Private - Meningococcal Meningitis Vaccine Market (Million US$), 2017 - 2022
Figure 12: Private - Forecast for Meningococcal Meningitis Vaccine Market (Million US$), 2023 - 2027
Figure 13: Public - Meningococcal Meningitis Vaccine Doses (Million), 2017 - 2022
Figure 14: Public - Forecast for Meningococcal Meningitis Vaccine Doses (Million), 2023 - 2027
Figure 15: Private - Meningococcal Meningitis Vaccine Doses (Million), 2017 - 2022
Figure 16: Private - Forecast for Meningococcal Meningitis Vaccine Doses (Million), 2023 - 2027
Figure 17: China - Pneumococcal Vaccines Market (Million US$), 2017 - 2022
Figure 18: China - Forecast for Pneumococcal Vaccines Market (Million US$), 2023 - 2027
Figure 19: China - Pneumococcal Vaccines Doses Doses (Million), 2017 - 2022
Figure 20: China - Forecast for Pneumococcal Vaccines Doses Doses (Million), 2023 - 2027
Figure 21: China - DTP Vaccine Market (Million US$), 2017 - 2022
Figure 22: China - Forecast for DTP Vaccine Market (Million US$), 2023 - 2027
Figure 23: China - DTaP Vaccine Market Market (Million US$), 2017 - 2022
Figure 24: China - Forecast for DTaP Vaccine Market Market (Million US$), 2023 - 2027
Figure 25: China - DTcP Vaccine Market Market (Million US$), 2017 - 2022
Figure 26: China - Forecast for DTcP Vaccine Market Market (Million US$), 2023 - 2027
Figure 27: DTP - Public Vaccine Doses (Million), 2017 - 2022
Figure 28: DTP - Forecast for Public Vaccine Doses (Million), 2023 - 2027
Figure 29: DTP - Private Vaccine Doses (Million), 2017 - 2022
Figure 30: DTP - Forecast for Private Vaccine Doses (Million), 2023 - 2027
Figure 31: China - Rabies Vaccine Market (Million US$), 2017 - 2022
Figure 32: China - Forecast for Rabies Vaccine Market (Million US$), 2023 - 2027
Figure 33: China - Ebola Vaccine Market (Million US$), 2018 - 2022
Figure 34: China - Forecast for Ebola Vaccine Market (Million US$), 2023 - 2027
Figure 35: Product - MCV4 Vaccine Market (Million US$), 2020 - 2022
Figure 36: Product - Forecast for MCV4 Vaccine Market (Million US$), 2023 - 2027
Figure 37: Product - MPSV4 Vaccine Market (Million US$), 2017 - 2022
Figure 38: Product - Forecast for MPSV4 Vaccine Market (Million US$), 2023 - 2027
Figure 39: Product - MCV2-Hib Vaccine Market (Million US$), 2017 - 2022
Figure 40: Product - Forecast for MCV2-Hib Vaccine Market (Million US$), 2023 - 2027
Figure 41: Product - MCV2 Vaccine Market (Million US$), 2017 - 2022
Figure 42: Product - Forecast for MCV2 Vaccine Market (Million US$), 2023 - 2027
Figure 43: Product - MPSV2 and Men A Vaccine Market (Million US$), 2017 - 2022
Figure 44: Product - Forecast for MPSV2 and Men A Vaccine Market (Million US$), 2023 - 2027
Figure 45: Product - PCV13 Vaccine Market (Million US$), 2017 - 2022
Figure 46: Product - Forecast for PCV13 Vaccine Market (Million US$), 2023 - 2027
Figure 47: Product - PPV23 Vaccine Market (Million US$), 2017 - 2022
Figure 48: Product - Forecast for PPV23 Vaccine Market (Million US$), 2023 - 2027
Figure 49: Product - Others Vaccine Market (Million US$), 2017 - 2022
Figure 50: Product - Forecast for Others Vaccine Market (Million US$), 2023 - 2027
Figure 51: Sinopharm Group (China National Biotec Group Company Limited) - Global Revenue (Billion US$), 2017 - 2022
Figure 52: Sinopharm Group (China National Biotec Group Company Limited) - Forecast for Global Revenue (Billion US$), 2023 - 2027
Figure 53: Hualan Biological Engineering Inc - Global Revenue (Million US$), 2017 - 2022
Figure 54: Hualan Biological Engineering Inc - Forecast for Global Revenue (Million US$), 2023 - 2027
Figure 55: Chongqing Zhifei Biological Products Co Ltd - Global Revenue (Million US$), 2017 - 2022
Figure 56: Chongqing Zhifei Biological Products Co Ltd - Forecast for Global Revenue (Million US$), 2023 - 2027
Figure 57: Walvax Biotechnology Co Ltd - Global Revenue (Million US$), 2017 - 2022
Figure 58: Walvax Biotechnology Co Ltd - Forecast for Global Revenue (Million US$), 2023 - 2027
Figure 59: Beijing Tiantan Biological Products Corp Ltd - Global Revenue (Million US$), 2017 - 2022
Figure 60: Beijing Tiantan Biological Products Corp Ltd - Forecast for Global Revenue (Million US$), 2023 - 2027
Figure 61: Sinovac Biotech - Global Revenue (Million US$), 2017 - 2022
Figure 62: Sinovac Biotech - Forecast for Global Revenue (Million US$), 2023 - 2027
Figure 63: Shenzhen Kangtai Biological Products Co Ltd - Global Revenue (Million US$), 2017 - 2022
Figure 64: Shenzhen Kangtai Biological Products Co Ltd - Forecast for Global Revenue (Million US$), 2023 - 2027
List of Tables:
Table 01: China - Vaccine Market Share by Sectors (Percent), 2017 - 2021
Table 02: China - Forecast for Vaccine Market Share by Sectors (Percent), 2022 - 2027
Table 03: China - Vaccine Doses Share by Sectors (Percent), 2017 - 2021
Table 04: China - Forecast for Vaccine Doses Share by Sectors (Percent), 2022 - 2027
Table 05: China - Vaccine Market Share by Products Type (Percent), 2017 - 2021
Table 06: China - Forecast for Vaccine Market Share by Products Type (Percent), 2022 - 2027
Table 07: China - Vaccine Market Share by Disease Type (Percent), 2017 - 2021
Table 08: China - Forecast for Vaccine Market Share by Disease Type (Percent), 2022 - 2027
Companies Mentioned
- Sinopharm Group (China National Biotec Group Company Limited)
- Hualan Biological Engineering Inc
- Chongqing Zhifei Biological Products Co Ltd
- Walvax Biotechnology Co Ltd
- Beijing Tiantan Biological Products Corp Ltd
- Sinovac Biotech
- Shenzhen Kangtai Biological Products Co Ltd
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 170 |
| Published | January 2023 |
| Forecast Period | 2022 - 2027 |
| Estimated Market Value ( USD | $ 6.91 Billion |
| Forecasted Market Value ( USD | $ 12.16 Billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | China |
| No. of Companies Mentioned | 7 |
